Fig. 2: Protein Lysine 2-Hydroxyisobutyrylation Exerts Changes in the Rg3-treated TAC-Induced Cardiac Hypertrophy. | Cell Death & Disease

Fig. 2: Protein Lysine 2-Hydroxyisobutyrylation Exerts Changes in the Rg3-treated TAC-Induced Cardiac Hypertrophy.

From: Rg3 regulates myocardial pyruvate metabolism via P300-mediated dihydrolipoamide dehydrogenase 2-hydroxyisobutyrylation in TAC-induced cardiac hypertrophy

Fig. 2

A Western blot of different tissue lysates against anti-2-hydroxyisobutyryllysine antibody, n = 2–3 for each group. S: Sham, M: TAC, H: Rg3-20mg/kg group, L: Rg3-10mg/kg group. B The analytical strategy and method for global profiling of Khib on the TAC group and the Rg3-treated group by combining the affinity enrichment and proteomics techniques. C Volcano Chart Analysis of the Khib sites for the TAC group and the Rg3-treated group, n = 3 for each group. D The heat map showed the the 10 proteins with the most remarkable down-regulation by 2-hydroxyisobutyrylation. M: TAC, H: Rg3-20mg/kg group. E Reconstruction of glucose metabolism from omics data. The numbers in metabonomics and proteomics represented the change ratio of metabolites or enzymes of Rg3 treated compared with TAC group. F, G Heart homogenates were immunoprecipitated with anti-DLD or anti-2-hydroxyisobutyryl-lysine agarose beads, and probed with anti-2-hydroxyisobutyryl-lysine, anti-DLD, and anti-β-actin antibody. The representative immunoblots were presented, n = 3 for each group. The data were analyzed using Kruskal wallis test, #p < 0.05, ##p < 0.01 versus Sham group, *p < 0.05, **p < 0.01 versus TAC group.

Back to article page